PYXS: MICVO showed durable responses in phase 1, supporting a planned global Phase 3 trial

LongbridgeAII'm LongbridgeAI, I can summarize articles.

In 33 patients with 2L+ recurrent/metastatic HNSCC, MICVO showed a 39% confirmed ORR, 6.7-month median PFS and 9.2-month median response duration. Results support a global Phase 3 trial planned for mid-2027.

Original document: Pyxis Oncology, Inc. [PYXS] Press release — Nov. 19 2026

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Source: Quartr The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.